Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP7 | O15540 | 1/20 | 0.54 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31518977 | 1.00 | FABP7 (0.54) | FABP7FABP5TSHRALDH1A1NPC1 | |
| SCHEMBL2703515 | 0.98 | FABP7 (0.55) | FABP7FABP5TSHRALDH1A1NPC1 | |
| SCHEMBL3664444 | 0.95 | TSHR (0.58) | FABP7FABP5TSHRALDH1A1NPC1 | |
| SCHEMBL10917021 | 0.91 | FABP7 (0.58) | FABP7FABP5TSHRALDH1A1NPC1 | |
| SCHEMBL6666657 | 0.91 | FABP7 (0.58) | FABP7FABP5TSHRALDH1A1NPC1 | |
| SCHEMBL280126 | 0.91 | FABP7 (0.58) | FABP7FABP5TSHRALDH1A1NPC1 | |
| SCHEMBL17365604 | 0.91 | CYP3A4 (0.53) | FABP7FABP5TSHRALDH1A1NPC1 | |
| SCHEMBL11982183 | 0.91 | CYP3A4 (0.53) | FABP7FABP5TSHRALDH1A1NPC1 | |
| Hydrochloric Acid SCHEMBL27944947 | 0.89 | FABP7 (0.57) | FABP7FABP5TSHRALDH1A1NPC1 | |
| Hydrochloric Acid SCHEMBL27765522 | 0.89 | FABP7 (0.57) | FABP7FABP5TSHRALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211884-B2 | 2,2-Dimethyl-4-oxo-4-(4-{4-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-phenyl}-[1,4]diazepan-1-yl)-butyric acid, hydrochloride; obesity, type II diabetes mellitus and metabolic syndrome | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | claimed |
| WO-2010017040-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC (US) | 2010-02-11 | — | — | WO | claimed |
| US-20100035864-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2010-02-11 | — | — | US | claimed |
| EP-0687249-A1 | BALANOIDS | ELI LILLY AND COMPANY (US) | 1995-12-20 | — | — | EP | claimed |
| WO-1994020062-A2 | BALANOIDS AS PROTEIN KINASE C INHIBITORS | ELI LILLY AND COMPANY (US) | 1994-09-15 | — | — | WO | claimed |
| JP-62006681-A | — | — | None | — | — | JP | disclosed |
| EP-4743522-A1 | COMPOSITION OF THERMOPLASTIC POLYMER, PLASTICIZER, AND LOW MELTING POLYMER | Avient Corporation (US) | 2026-05-20 | — | — | EP | disclosed |
| CN-119591496-A | Method for catalyzing cycloalkane oxidative carbonylation reaction by metal-based ionic liquid | 中国科学院过程工程研究所 | 2025-03-11 | — | — | CN | disclosed |
| WO-2025019282-A1 | COMPOSITION OF THERMOPLASTIC POLYMER, PLASTICIZER, AND LOW MELTING POLYMER | AVIENT CORPORATION (US) | 2025-01-23 | — | — | WO | disclosed |
| US-20250019533-A1 | COMPOSITION OF THERMOPLASTIC POLYMER, PLASTICIZER, AND LOW MELTING POLYMER | AVIENT CORPORATION (US) | 2025-01-16 | — | — | US | disclosed |
| CN-117677603-A | Cyclohexane lipids for nucleic acid transfection and uses thereof | 捷克有机化学和生物化学研究院 | 2024-03-08 | — | — | CN | disclosed |
| WO-2023086399-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| CN-1300730-A | Process for preparing aminoformate compounds with CO2 instead of severely toxic optical gas | SHANGHAI INST ORGANIC CHEM (CN) | 2001-06-27 | — | — | CN | disclosed |
| EP-1004621-A1 | GAMMA-RAY STABILIZER AND THERMOPLASTIC POLYMER COMPOSITION CONTAINING THE SAME | TEIJIN LIMITED (JP) | 2000-05-31 | — | — | EP | disclosed |
| EP-0687249-A1 | BALANOIDS | ELI LILLY AND COMPANY (US) | 1995-12-20 | — | — | EP | disclosed |
| WO-1994020062-A2 | BALANOIDS AS PROTEIN KINASE C INHIBITORS | ELI LILLY AND COMPANY (US) | 1994-09-15 | — | — | WO | disclosed |
| CN-1015361-B | ENANTIOMERIC GLUTARAMIDE DIURETIC AGENTS | PFIZER (US) | 1992-02-05 | — | — | CN | disclosed |
| CN-1037704-A | The glutaramide diuretic agents of enantiomorph | PFIZER (US) | 1989-12-06 | — | — | CN | disclosed |
| JP-S626681-A | PROTEASE INHIBITOR | SHOWA DENKO KK | 1987-01-13 | — | — | JP | disclosed |
| US-4178317-A | Manufacture of olefinically unsaturated aliphatic or cycloaliphatic hydrocarbons | BASF AKTIENGESELLSCHAFT (DE) | 1979-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035864-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | FABP7 616/4885FABP5 447/4885TSHR 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.